Alaunos Therapeutics Inc.

TCRT10 Dec 2024
Healthcare
$2.15
+0.04 (+4.23%)
Lowest Today
$2.14
Highest Today
$2.23
Today’s Open
$2.15
Prev. Close
$2.13
52 Week High
$33
52 Week Low
$1.95
To Invest in Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc.

Healthcare
TCRT10 Dec 2024
+0.04 (+4.23%)
1M
3M
6M
1Y
5Y
Low
$2.14
Day’s Range
High
$2.23
2.14
52 Week Low
$1.95
52-Week Range
52 Week High
$33
1.95
1 Day
-
1 Week
-15.81%
1 month return
+1.18%
3 month return
-9.74%
6 month return
+104.8%
1 Year return
+169.44%
3 Years return
-88.36%
5 Years return
-97.2%
10 Years return
-
Institutional Holdings
MSD Partners, L.P.
6.31
Vanguard Group Inc
2.83
Vanguard Institutional Extnd Mkt Idx Tr
1.28
Vanguard Total Stock Mkt Idx Inv
1.08
Geode Capital Management, LLC
1.02
Fidelity Extended Market Index
0.56
BlackRock Extended Equity Market K
0.19

Market Status

Fundamentals
Market Cap
3.41 mln
PB Ratio
1.25
PE Ratio
0
Enterprise Value
-2.65 mln
Total Assets
8.26 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Organisation
Alaunos Therapeutics Inc.
Employees
1
Industry
Biotechnology
CEO
Mr. Dale Curtis Hogue Jr.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities